Login / Signup

Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity.

Maria DichiaraFrancesca Alessandra AmbrosioSang Min LeeMa Carmen Ruiz CanteroJessica LombinoAdriana CoricelloGiosuè CostaDhara ShahGiuliana CostanzoLorella PasquinucciKyung No SonGiuseppe CosentinoRafael González-CanoAgostino MarrazzoVinay Kumar AakaluEnrique J CobosStefano AlcaroEmanuele Amata
Published in: Journal of medicinal chemistry (2023)
The design and synthesis of a series of 2,7-diazaspiro[4.4]nonane derivatives as potent sigma receptor (SR) ligands, associated with analgesic activity, are the focus of this work. In this study, affinities at S1R and S2R were measured, and molecular modeling studies were performed to investigate the binding pose characteristics. The most promising compounds were subjected to in vitro toxicity testing and subsequently screened for in vivo analgesic properties. Compound 9d ( AD258 ) exhibited negligible in vitro cellular toxicity and a high binding affinity to both SRs ( K i S1R = 3.5 nM, K i S2R = 2.6 nM), but not for other pain-related targets, and exerted high potency in a model of capsaicin-induced allodynia, reaching the maximum antiallodynic effect at very low doses (0.6-1.25 mg/kg). Functional activity experiments showed that S1R antagonism is needed for the effects of 9d and that it did not induce motor impairment. In addition, 9d exhibited a favorable pharmacokinetic profile.
Keyphrases
  • neuropathic pain
  • anti inflammatory
  • binding protein
  • chronic pain
  • small molecule
  • spinal cord
  • spinal cord injury
  • pain management
  • high glucose
  • drug induced
  • mass spectrometry
  • oxide nanoparticles